Medikamentöse Therapiestrategien des Magenkarzinoms

Magenkarzinome sind in Deutschland bei Frauen für 2,4% und bei Männern für 3,5% der Krebsneuerkrankungen verantwortlich und gehen mit einer hohen Letalitätsrate einher. In der Therapie wird zwischen einer lokalen und einer metastasierten Tumorerkrankung unterschieden. Neue Behandlungsverfahren wie Immuntherapie und zielgerichtete Therapie halten in beiden Fällen Einzug in die derzeitigen Therapiestrategien und verbessern damit die Prognose der Patient*innen.

Schlüsselwörter

Magenkarzinom - perioperative Chemotherapie - palliative Chemotherapie - Immuntherapie - zielgerichtete Therapie

• Literatur

• 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 2021; 71: 209-249
• 2 National Cancer Institute. SEER Cancer Statistics Review 1975–2016, Cancer of the Stomach (Invasive) [Internet]. Accessed May 15, 2023 at: https://seer.cancer.gov/archive/csr/1975_2016/
• 3 Lordick F, Carneiro F, Cascinu S. et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1005-1020
• 4 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209
• 5 Gertsen EC, Brenkman HJF, van Hillegersberg R. et al. 18 F-fludeoxyglucose-positron emission tomography/computed tomography and laparoscopy for staging of locally advanced gastric cancer: A multicenter prospective Dutch cohort study (PLASTIC). JAMA Surg 2021; 156: e215340
• 6 Moehler M, Al-Batran SE, Andus T. et al. S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0. Z Gastroenterol 2019; 57: 1517-632
• 7 Cunningham D. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20
• 8 Al-Batran S-E, Hofheinz RD, Pauligk C. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016; 17: 1697-708
• 9 Al-Batran S-E, Homann N, Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet 2019; 393: 1948-1957
• 10 Becker K, Mueller JD, Schulmacher C. et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy: Response of Gastric Carcinoma to Chemotherapy. Cancer 2003; 98: 1521-1530
• 11 Smyth E, Mauer M, Cella C. et al. O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study. Annals of Oncology 2023; 34: S182-3
• 12 The GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA 2010; 303: 1729
• 13 Cats A, Jansen EPM, van Grieken NCT. et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 2018; 19: 616-628
• 14 Al-Batran S-E, Lorenzen S, Thuss-Patience PC. et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. J Clin Oncol 2022; 40: 4003
• 15 Janjigian YY, Shitara K, Moehler M. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet 2021; 398: 27-40
• 16 Shitara K, Rha SY, Wyrwicz LS. et al. LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study. Annals of Oncology 2023; 34: S1316
• 17 Al-Batran SE, Lorenzen S, Thuss-Patience PC. et al. A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK. JCO 2023; 41: TPS4177-TPS4177
• 18 André T, Tougeron D, Piessen G. et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA phase II Study. J Clin Oncol 2022; 41: 255-265
• 19 Pietrantonio F, Raimondi A, Lonardi S. et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). J Clin Oncol 2023; 41: 358-358
• 20 Pietrantonio F, Miceli R, Raimondi A. et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol 2019; 37: 3392-3400
• 21 Hofheinz R, Hegewisch-Becker S, Kunzmann V. et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer 2021; 149: 1322-1331
• 22 Al-Batran SE, Haag GM, Ettrich TJ. et al. 1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma. Ann Oncol 2020; 31: S899
• 23 Wagner A, Grabsch H, Mauer M. et al. O-5 Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) – subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG. Annals of Oncology 2023; 34: S182
• 24 Glatz T, Verst R, Kuvendjiska J. et al. Pattern of recurrence and patient survival after perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin and docetaxel (FLOT) for locally advanced esophagogastric adenocarcinoma in patients treated outside clinical trials. J Clin Med 2020; 9: 2654
• 25 Ajani JA, D’Amico TA, Bentrem DJ. et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Nat Comprehensive Cancer Network 2022; 20: 167-192
• 26 Hall PS, Swinson D, Cairns DA. et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of Life and cancer control among older and frail patients with advanced gastroesophageal cancer: The GO2 phase 3 randomized clinical trial. JAMA Oncology 2021; 7: 869-877
• 27 Sama S, Nevala-Plagemann CD, Smith J. et al. Real-world outcomes with front-line doublet versus triplet chemotherapy in advanced gastroesophageal adenocarcinoma. J Clin Oncol 2023; 41: 313
• 28 Zaanan A, Bouche O, De La Fouchardiere C. et al. LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD. Annals of Oncology 2023; 34: S1318
• 29 Van Cutsem E, Bang YJ, Feng-Yi F. et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 2015; 18: 476-484
• 30 Bang YJ, Van Cutsem E, Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
• 31 Porth I, Hirsch D, Ceribas Y. et al. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma. Eur J Cancer 2023; 183: 119-130
• 32 Tabernero J, Hoff PM, Shen L. et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 2018; 19: 1372-1384
• 33 Thuss-Patience PC, Shah MA, Ohtsu A. et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 2017; 18: 640-53
• 34 Janjigian YY, Kawazoe A, Yañez P. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021; 600: 727-730
• 35 Janjigian YY, Kawazoe A, Bai Y. et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. The Lancet 2023; 402: 2197-208
• 36 Janjigian Y, Rha S, Oh D. et al. SO-7 Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial. Ann Oncology 2022; 33: S358-S359
• 37 Shitara K, Bang YJ, Iwasa S. et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 2020; 382: 2419-2430
• 38 Van Cutsem E, Di Bartolomeo M, Smyth E. et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. The Lancet Oncology 2023; 24: 744-56
• 39 Lordick F, Al-Batran SE, Arnold D. et al. Onkopedia Leitlinie Magenkarzinom. 2024 Accessed December 22, 2023 at: https://www.onkopedia.com/de/onkopedia/guidelines/magenkarzinom/@@guideline/html/index.htm
• 40 National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Antiemesis Version 1.2023 — January 25. 2023 Accessed May 15, 2023 at: www.nccn.org/patients
• 41 Janjigian YY, Shitara K, Moehler M. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet 2021; 398: 27-40
• 42 Shen L, Bai Y, Lin X. et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up. J Clin Oncol 2023; 41: 353
• 43 Rha SY, Oh D-Y, Yañez P. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncology 2023; 24: 1181-95
• 44 Moehler MH, Kato K, Arkenau H-T. et al. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). J Clin Oncol 2023; 41: 286
• 45 Xu RH, Oh DY, Kato K. et al. LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study. Annals of Oncology 2023; 34: S1320-1321
• 46 Wilke H, Muro K, Van Cutsem E. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235
• 47 Fuchs CS, Tomasek J, Yong CJ. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39
• 48 Lorenzen S, Thuss-Patience P, Pauligk C. et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer 2022; 165: 48-57
• 49 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38: 1-10
• 50 Shitara K, Doi T, Dvorkin M. et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19: 1437-1448
• 51 Pavlakis N, Shitara K, Sjoquist KM. et al. INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG). J Clin Oncol 2023; 41: LBA294-LBA294
• 52 Sahin U, Türeci Ö, Manikhas G. et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 2021; 32: 609-619
• 53 Shitara K, Lordick F, Bang Y-J. et al. Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study. J Clin Oncol 2023; 41: LBA292-LBA292
• 54 Ajani JA, Lordick F, Bang YJ. et al. 135MO Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Annals of Oncology 2023; 34: S1524-1525
• 55 Lordick F, Shah MA, Shitara K. et al. 134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Annals of Oncology 2023; 34: S1524
• 56 Wainberg ZA, Enzinger PC, Kang Y-K. et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncology 2022; 23: 1430-1440
• 57 Al-Batran S-E, Homann N, Pauligk C. et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: The AIO-FLOT3 trial. JAMA Oncol 2017; 3: 1237
• 58 Chevallay M, Wassmer C-H, Iranmanesh P. et al. Multimodal treatment in oligometastatic gastric cancer. World J Gastrointest Oncol 2022; 14: 434-449